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Candida auris is an emerging fungal pathogen that exhibits resistance to multiple drugs,
including the most commonly prescribed antifungal, fluconazole. Here, we use a combina-
torial screening approach to identify a bis-benzodioxolylindolinone (azoffluxin) that syner-
gizes with fluconazole against C. auris. Azoffluxin enhances fluconazole activity through the
inhibition of efflux pump Cdr1, thus increasing intracellular fluconazole levels. This activity is
conserved across most C. auris clades, with the exception of clade III. Azoffluxin also inhibits
efflux in highly azole-resistant strains of Candida albicans, another human fungal pathogen,
increasing their susceptibility to fluconazole. Furthermore, azoffluxin enhances fluconazole
activity in mice infected with C. auris, reducing fungal burden. Our findings suggest that
pharmacologically targeting Cdr1 in combination with azoles may be an effective strategy to
control infection caused by azole-resistant isolates of C. auris.
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The rise in antimicrobial resistance has become a majorthreat to public health1. Although the focus has primarilybeen on pan-resistant bacteria, there is growing concern
over the multidrug-resistant fungal pathogen, Candida auris. This
emerging pathogen has galvanized researchers, health care
workers, and the media due to its high rates of drug resistance
and transmissibility2,3. In its most recent report, the U.S. Centers
for Disease Control and Prevention classified C. auris as one of
only five pathogens that are the most urgent threat to public
health4. Thus, the emergence of C. auris highlights the need for
more therapeutic options to combat drug-resistant fungal
infections.
C. auris has an interesting history. Since it was first identified
in 2009 in Japan5, genomic analyses have revealed the near
simultaneous emergence of distinct lineages across six continents,
encompassing over 30 countries within the past ~400 years6,7.
Currently, the majority of C. auris isolates fall into four major
geographical clades: South Asian (I), East Asian (II), African (III),
and South American (IV)6,7. This species has a remarkable ability
to persist on human skin and other surfaces for extended periods
of time, which facilitates hospital transmission amongst patients
who are already vulnerable to infection2,8,9. Additionally, the
prevalence of drug resistance amongst C. auris isolates is wide-
spread as recent studies show that over 80% of clinical isolates are
resistant to the azole antifungal fluconazole3,7. Resistance levels
vary significantly between clades, with some isolates exhibiting
resistance to all three major antifungal drug classes available to
treat systemic infections3,7.
The prevalence of fluconazole resistance amongst C. auris
isolates is challenging from a clinical perspective as fluconazole is
the most widely administered antifungal. This is due to its oral
bioavailability, broad spectrum of activity, and favorable safety
profile10. Fluconazole inhibits the biosynthesis of ergosterol, the
major sterol in fungal cell membranes, through inhibition of
lanosterol demethylase, which is encoded by ERG1111. Inhibition
leads to an increase in the Erg11 substrate lanosterol, and the
production of aberrant sterol intermediates, including 14-α-
methyl-3,6-diol12,13. Mechanisms of fluconazole resistance
amongst C. auris isolates are highly variable and often clade
specific, the nuances of which are still being elucidated. One
major mechanism of fluconazole resistance involves point
mutations in hot spot regions in its target gene ERG11, which are
known to confer resistance in other fungi14–16. In addition to
ERG11 mutations that are shared across all clades3,7, the most
common substitutions found in clade I and IV are Erg11Y132F or
Erg11K143R, whilst clade III isolates commonly have an
Erg11F126L substitution. Notably, strains from clade II generally
have no specific ERG11 mutations and include the most sensitive
isolates3,6,16. In addition to target alteration, C. auris encodes an
array of multidrug transporters, several of which are strongly
induced under various conditions, including fluconazole treat-
ment17–20. Finally, C. auris isolates possess other genetic altera-
tions that could confer fluconazole resistance, such as gene
duplication leading to a higher copy number of ERG1118, or
transcriptional upregulation of efflux pumps through mutations
in TAC1B21. Overall, the diversity of C. auris resistance
mechanisms is extensive, and the prevalence of fluconazole
resistance threatens to render this important therapeutic obsolete
in treatment of the rising number of C. auris infections world-
wide.
A well-established strategy to thwart drug resistance and
restore antimicrobial efficacy is the use of combination therapy,
which has been successfully implemented for many difficult to
treat infections, including HIV-AIDS, tuberculosis, and malaria10.
By identifying agents that re-sensitize pathogens to existing
therapeutics, the lifespan of existing antifungals could be
extended. In vitro data suggests combining existing antifungals
can be effective against C. auris22,23. An excellent example of the
potential value of combination therapy is provided by iKIX1, a
novel compound that inhibits interaction of the transcription
factor Pdr1 with the Mediator complex in the fungal pathogen
Candida glabrata, thus preventing upregulation of the multidrug
transporter Pdr524. Combination treatment with iKIX1 and flu-
conazole abrogated intrinsic azole resistance and improved sur-
vival in a murine model of C. glabrata infection24. Clearly, the
inclusion of agents capable of impairing the most common,
readily anticipated modes of antifungal resistance provides a
rational, readily implemented strategy in the development of
more efficacious combination treatment regimens.
In this study, we applied a combinatorial approach to screening
of a chemically diverse library against an azole-resistant strain of
C. auris to identify molecules that specifically enhanced the
activity of fluconazole. We identified azoffluxin as a compound
that synergized with fluconazole by increasing intracellular flu-
conazole accumulation through inhibition of the major multidrug
efflux transporter Cdr1. Using azoffluxin as a chemical probe, we
established that efflux is a major mechanism of resistance in
isolates belonging to three of the four major C. auris clades.
Notably, clade III isolates carrying specific mutations in ERG11,
in addition to upregulating the multi-drug transporter Mdr1,
remained resistant to fluconazole in the presence of azoffluxin,
despite the compound blocking efflux of Nile red and fluconazole
in these isolates. Azoffluxin showed cross-species activity by
potentiating fluconazole activity against a resistant isolate of
Candida albicans, the most common human fungal pathogen25.
In culture, azoffluxin transformed fluconazole from ineffective to
highly active in rescuing mammalian cells infected with drug-
resistant C. auris. In mice infected with drug-resistant C. auris,
azoffluxin not only enhanced fluconazole activity but also
reduced fungal burden by ~1000-fold as a single agent. Collec-
tively, our findings demonstrate pharmacological inhibition of
Cdr1 function may be an effective way to control infection with
azole-resistant isolates of C. auris.
Results
Chemical screen identifies azole-synergizing compound. To
identify novel compounds that enhance the activity of fluconazole
against C. auris, we screened a diversity-oriented, synthetic
library created by Boston University’s Center for Molecular
Discovery (BU-CMD). This library of 2454 molecules, many
natural product-inspired, has been curated to encompass greater
structural complexity than conventional chemical libraries26,
which is a feature that increases the likelihood of identifying
compounds with bioactivity against microorganisms27,28. The
BU-CMD library was screened at 50 μM in the absence or pre-
sence of a concentration of fluconazole that inhibited growth of
the fluconazole-resistant clade I C. auris strain VPCI 673/P/12 by
~20%. Through Sanger sequencing we confirmed this strain
harbored both an Erg11K143R substitution and Tac1bA640V sub-
stitution. Compounds that reduced growth after 48 h compared
to the control by 7-median absolute deviations from the median
alone were classified as single agent antifungals; their mechanism
of action has been described elsewhere29. Compounds for which
antifungal activity was only observed in combination with flu-
conazole were classified as fluconazole potentiators (Fig. 1a). Of
the three fluconazole potentiators identified, we prioritized the
bis-benzodioxolylindolinone CMLD012336, a 3,3-diarylated oxi-
ndole hereafter referred to as azoffluxin, due to its strong
synergistic interaction with fluconazole against a resistant strain
of C. auris, Ci6684 (Fig. 1b, c). Ci6684 harbors an Erg11Y132F
substitution but no known activating substitutions in Tac1b
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(Tac1bWT). The fractional inhibitory concentration index (FICI)
calculated for the combination was 0.25, with values <0.5 indi-
cating a synergistic interaction (Fig. 1b)30. As a complementary
approach, we used fluconazole E-test strips to determine whether
synergy could also be observed on solid medium. In the absence
of azoffluxin, C. auris grew up to the highest concentration of
fluconazole present on the E-test strip. Strikingly, the presence of
azoffluxin (50 μM) reduced the fluconazole minimum inhibitory
concentration (MIC) >8-fold, from >256 μg/mL to 32 μg/mL on
YPD agar (Figs. 1d and S1a). Finally, given the potent synergy
against C. auris, we tested fluconazole-sensitive laboratory strains
of C. albicans (SN95), C. glabrata (BG2), and Saccharomyces
cerevisiae (BY4741), to represent diverse fungi. Interestingly,
azoffluxin did not enhance the activity of fluconazole against any
of these species even in the presence of the highest concentration
of fluconazole that did not impair growth in each species on its
own (Fig. 1e). Thus, either azoffluxin exerts species-selective
activity or it only enhances fluconazole activity in the context of
pre-existing resistance, but not in fluconazole-sensitive
organisms.
Azoffluxin enhances azole efficacy in a Cdr1-dependent man-
ner. Of the many ways in which drug combinations can exert a
synergistic effect, a common mechanism involves one compound
enhancing the biological effect of another agent by targeting
parallel pathways or improving bioavailability31. To investigate
these possibilities for azoffluxin, we profiled the sterol composi-
tion of C. auris with or without prior exposure to compounds13.
Our hypothesis was that if azoffluxin heightens the effects of
fluconazole-mediated Erg11 inhibition, a low concentration of
fluconazole combined with azoffluxin would have an equally
profound impact on sterol composition as a high concentration of
fluconazole alone. Using LC-MS, we evaluated how exposure of
C. auris to a combination of azoffluxin and fluconazole for 18 h
affected the abundance of three membrane sterols: ergosterol,
lanosterol, and the azole-induced aberrant sterol intermediate 14-
α-methyl-3,6-diol (Fig. 2a)12. Minimal changes in abundance of
these sterols were detected between untreated and azoffluxin-
treated cells. Compared to untreated cells, fluconazole treatment
resulted in significant 1.4-fold and 3.9-fold increases in ergosterol
and lanosterol, respectively, and a larger >250-fold increase in 14-
α-methyl-3,6-diol (p < 0.05; Fig. 2a). This suggested that while
exerting a minimal effect on growth, the low fluconazole con-
centration partially inhibited Erg11, causing a compensatory
upregulation in ergosterol biosynthesis. However, azoffluxin
dramatically amplified the impact of the low fluconazole con-
centration on sterol composition. Most notable was a >1000-fold
increase in 14-α-methyl-3,6-diol compared to untreated cells
(Fig. 2a). The relative abundance of all three sterols upon treat-
ment with both azoffluxin and a low concentration of fluconazole























Fig. 1 Screen of the BU-CMD library identifies azoffluxin as a fluconazole (FLC) potentiator against C. auris. a BU-CMD library was screened at 50 μM
in the presence or absence of 128 μg/mL of FLC in RPMI medium at 30 °C for 48 h. Growth of C. auris strain VPCI 673/P/12, as determined by optical
density at 600 nm (OD600), is plotted in the presence of each CMD compound alone and in combination with FLC. Dotted lines represent 7-median
absolute deviations from the median for each condition. Red circles indicate compounds that showed significant bioactivity. The shaded quadrant indicates
compounds that show enhanced activity in the presence of fluconazole, with azoffluxin shown as a filled red circle. b Checkerboard assays with azoffluxin
(CMLD012336) and FLC were performed in RPMI at 30 °C by titering 2-fold dilution series of azoffluxin and FLC. Growth in each well is presented in heat-
map format based on the OD600 of wells at 48 h relative to the no-drug control (see color bar). The fractional inhibitory concentration index (FICI) was
calculated to assess interaction effect, with a value <0.5 indicating synergy. c Structure of CMLD012336 (azoffluxin). d FLC Etest strips in the presence and
absence of 50 μM azoffluxin. C. auris cells (1 × 106) C. auris cells were plated on YPD agar, the E-test strip was added, and plates were incubated at 30 °C
for 24 h prior to imaging. e Dose-response assay based on 2-fold serial dilution of azoffluxin starting from 50 μM in the absence and presence of indicated
concentration of FLC for C. auris Ci6684 (Erg11Y132F), C. albicans (SN95), C. glabrata (BG2), or S. cerevisiae (BY4741), respectively. The highest FLC
concentrations that did not affect growth alone for each species was used. Dose-response assays were incubated for 48 h at 30 °C in RPMI. Growth in each
well was quantified by the OD600 of treated wells relative to the respective no-drug control (see color bar in b). Source data are provided as a Source
Data file.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20183-3 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:6429 | https://doi.org/10.1038/s41467-020-20183-3 | www.nature.com/naturecommunications 3
cells with a higher concentration of fluconazole alone, treatments
that both resulted in ~50% growth inhibition (Fig. 2a).
To determine whether azoffluxin enhances the effect of
fluconazole treatment by increasing intracellular fluconazole
abundance, we measured intracellular levels of fluconazole using
LC-MS after 1 h of treatment. We detected significantly more
intracellular fluconazole in the combination treatment group
compared to treatment with either a high or low fluconazole
concentration alone (p < 0.001; Fig. 2b). This amounted to a ~2.5-
fold increase in intracellular fluconazole in the combination
treatment compared to high fluconazole, despite the fact that
these treatments result in similar changes to the sterol profile of
the cell (Fig. 2a). This discrepancy is likely due to the variant time
points at which these assays were performed. Furthermore, we
were able to detect intracellular levels of azoffluxin, which were
increased in the combination treatment relative to azoffluxin
alone. These results indicate that this compound acts intracellu-
larly and fluconazole enhances its accumulation, perhaps due to
the disruption of membrane homeostasis by azoles (Fig. 2b).
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with fluconazole by increasing the intracellular accumulation of
fluconazole through an undetermined mechanism that next we
sought to define.
In pursuing mechanistic studies, we reasoned that an increase
in intracellular azole accumulation could be caused either by
enhancing permeability or by impeding drug efflux. To
discriminate between these two models, we first tested the
hypothesis that the increase in intracellular fluconazole caused by
azoffluxin treatment resulted from impairment of multidrug
efflux transporter activity. Impairment could be achieved by
either a transcriptional mechanism that reduces the expression of
genes encoding transporters or through a post-transcriptional
mechanism. In order to evaluate potential transcriptional effects,
we profiled the relative expression of six putative C. auris efflux
genes, identified by Muñoz and coworkers18, following treatment
with azoffluxin, fluconazole, or a combination of the two
compounds (Fig. S1b). Of the six transporter genes assessed,
those encoding the putative ABC transporters Cdr1
(B9J08_000164) and Cdr4-1 (B9J08_000479) demonstrated
similar expression profiles. At exposures to azoffluxin alone,
which had no effect on growth, we saw a concentration-
dependent increase in both CDR1 and CDR4-1 transcript levels,
which was greater than the induction observed upon treatment
with fluconazole (Figs. 2c and S1b). Furthermore, we observed a
greater increase in CDR1 and CDR4-1 expression upon
combination treatment than the increase seen with any individual
compound treatment (Fig. 2c). The observation that azoffluxin
causes an increase in transcript level of two efflux genes but
increases intracellular accumulation of fluconazole, suggested a
model in which azoffluxin directly inhibits efflux transporter
function post-transcriptionally, resulting in the compensatory
upregulation of efflux gene expression32,33.
To test our model experimentally, we determined whether
azoffluxin directly inhibited transporter function by monitoring
accumulation within C. auris of the relatively promiscuous efflux
pump substrate Nile red34. Flow cytometry revealed an 18.7-fold
increase in relative cell-associated Nile red signal caused by
treatment with azoffluxin (50 μM; Fig. 2d, e). To determine if
Cdr1 and/or Cdr4-1 were relevant targets of azoffluxin, we
utilized a C. auris strain in which CDR1 had been deleted35, and
also generated a CDR4-1 deletion strain. If azoffluxin acts by
inhibiting the activity of either transporter, then deletion of that
transporter should reduce or eliminate the increase in Nile red
accumulation caused by azoffluxin treatment. Although deletion
of these efflux genes did not completely block the increase in Nile
red accumulation caused by azoffluxin treatment, the magnitude
of the increase was significantly diminished (p < 0.05) in the
cdr1Δ strain (Figs. 2e, S2, and S3a), implicating Cdr1 as a likely
target of azoffluxin in C. auris. It is possible that other C. auris
transporters are also targets of azoffluxin, as Nile red signal was
still enhanced upon azoffluxin treatment in the absence of CDR1
or CDR4-1. However, Cdr4-1 is unlikely to be a relevant target
given that loss of this transporter had no significant effect on the
increase in Nile Red staining caused by azoffluxin.
Encouraged by the effects seen on Nile red as a model efflux
substrate, we next assessed the functional relevance of Cdr1 for
potentiation of fluconazole activity by azoffluxin. As would be
expected if azoffluxin enhances fluconazole activity via inhibition
of Cdr1, we found that deletion of CDR1 abolished the ability of
azoffluxin to potentiate the antifungal activity of fluconazole
(Fig. 2f). In dose-response assays, deletion of CDR1 reduced
fluconazole MIC to that observed upon combination with
azoffluxin in a wild-type background (Fig. 2f). In contrast,
deletion of CDR4-1 did not alter fluconazole sensitivity nor the
ability of azoffluxin to potentiate fluconazole (Fig. 2f). This
finding fits with previous reports in C. albicans that implicate
Cdr1 in azole efflux but not Cdr4-1, despite both being
transcriptionally upregulated in response to fluconazole36,37.
Given the extensive range of substrates that Cdr1 is reported to
efflux, we investigated whether azoffluxin potentiated the effects
of other intracellularly acting compounds to the same extent as
deletion of CDR1. Consistent with our model for its mode of
action, azoffluxin sensitized C. auris to the compounds gepinacin,
cerulenin, and cycloheximide to the same extent as CDR1
deletion, with no further sensitization to these compounds
observed by azoffluxin in the CDR1 null (Fig. 3). Although
mechanistically diverse, these compounds all act intracellularly
and are known to be Cdr1 efflux substrates38,39. In contrast,
azoffluxin had no impact on sensitivity to the extracellularly
acting compounds caspofungin and amphotericin B10 (Fig. 3).
Considering all these findings, we conclude that azoffluxin
enhances the antifungal activity of intracellularly acting com-
pounds, such as fluconazole, by inhibiting drug transporters, most
notably Cdr1, in C. auris.
Azoffluxin is active against diverse C. auris strains. Given the
extensive genetic diversity identified amongst different clades of
C. auris3,7,18, we investigated whether azoffluxin synergized with
fluconazole against representative isolates from all four major
clades. Intriguingly, when synergistic activity was assessed by
checkerboard assay, azoffluxin potentiated fluconazole in multiple
isolates from three of the four major clades. The clade III isolates
from South Africa were the exception (Fig. 4). Clade III is gen-
erally distinguishable from the others by both a V125A and
Fig. 2 Azoffluxin increases intracellular accumulation of fluconazole (FLC) by inhibiting Cdr1-mediated efflux in C. auris. a Abundance of ergosterol
(blue), lanosterol (red), and 14-α-methyl-3,6-diol (yellow) was determined in Ci6684 after compound treatment (• indicates concentrations used in
combination treatment) relative to internal cholesterol standard. Growth inhibition (%) caused by each treatment is presented in table. Data are presented
as mean ± SD of technical triplicates. Significance was determined by two-sided unpaired Student’s t test of condition compared to untreated; *p-value <
0.05, **p-value < 0.01. Fold-change for each treatment is indicated above the respective bar. b Intracellular concentrations of FLC (green) and azoffluxin
(gray) were measured after treatment for 1 h. Data are presented as mean ± SD of technical triplicates. Significance was determined by two-sided unpaired
Student’s t test, **p-value= 0.003, and ***p-value > 0.001. c Transcript levels of Ci6684 CDR1 (teal) and CDR4-1 (red) were measured. Cells were treated
with indicated concentrations of compound (• indicates concentrations used in combination treatment). Transcript levels were normalized to ACT1 and
GPD1 and are relative to the untreated control. Data are presented as mean ± SEM of technical triplicates. Significance of differences between untreated
control and treatment was determined by two-sided unpaired Student’s t test; *p-value < 0.05, **p-value < 0.01, ***p-value < 0.001. Fold-change is
indicated above each bar. d Ci6684 was treated with azoffluxin, followed by addition of Nile red. Scale bar represents 5 µm. e Cells from Fig. 2d and Fig. S2
were analyzed by flow cytometry. Histograms depict relative fluorescence intensity (PE-A) of events, values depict median fluorescence intensity (MFI).
Table displays mean fold-change in MFI of azoffluxin-treated, Nile red stained cells ± SD for biological triplicates. Significance of difference determined by a
two-sided unpaired Student’s t test, *p-value < 0.05 compared to parental average MFI. f Dose-response assays were conducted as in Fig. 1e. FLC was
applied as a 2-fold dilution series in the absence or presence of azoffluxin (50 µM). Growth was monitored and normalized to no-drug control (see color
bar). Source data are provided as a Source Data file.
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F126L substitution in Erg117 and the absence of drug-resistance
mutations in TAC1B, the transcriptional regulator of Cdr1 which
are commonly found in clades I and IV21 (e.g. the A640V sub-
stitution in our screening strain VPCI 673/P/12). Examining
whole genome sequences of 304 isolates representing each of the
four major clades7, identified a unique non-synonymous
substitution, N647T, in the transcription factor domain of Mrr1
(B9J08_004061) in 49 of 51 clade III isolates. In C. albicans, Mrr1
is a transcription factor that controls the expression of the major
facilitator superfamily (MFS) transporter Mdr1, which is involved
in fluconazole efflux40,41. Indeed, when expression of MDR1


















Fig. 3 Azoffluxin potentiates intracellular acting compounds against C. auris, to a similar degree as deletion of CDR1. Dose-response assays were
conducted with a C. auris Ci6684 parental strain in the absence and presence of 25 µM azoffluxin where indicated, as well as with a strain with the efflux
pump gene CDR1 deleted. Indicated compounds were titered in a 2-fold serial dilution. Growth was measured after 24 h in YPD as described in Fig. 1e (see
color bar). Source data are provided as a Source Data file.
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Fig. 4 Synergistic activity of azoffluxin is clade specific. Checkerboard assays were performed fluconaozle (FLC) and azoffluxin as described in Fig. 1b
with isolates from each major clade of C. auris. CDC identification number is followed by the clade number to which the isolate belongs. Relative growth
was measured in YPD medium after 24 h using OD600 and normalized to a no-drug control well (see color bar). The FICI calculated for each checkerboard
is shown in the top right of each plot, with values <0.5 indicating synergy, values >0.5 indicating no interaction, and N/A indicating an FICI that could not
be calculated due to a lack of growth inhibition. Source data are provided as a Source Data file.
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Fig. 5 Azoffluxin does not potentiate fluconazole (FLC) against most clade III isolates despite intracellular FLC accumulation and increased CDR1
expression. a Relative transcript levels ofMDR1 (B9J08_003981) and b relative transcript levels of CDR1 (B9J08_000164) were measured in clade I isolate
Ci6684 (gray) and clade III isolates B11221 (red) and B11222 (blue) (• indicates concentrations of FLC and azoffluxin used in combination (combo)
treatment). Data are presented as mean ± SEM of technical triplicates. A two-sided unpaired Student’s t test was performed to evaluate significance of
differences between Ci6684 and each clade III isolate *p-value < 0.05, **p-value < 0.01, and ***p-value < 0.001. c Flow cytometry was used to measure the
Nile red accumulation in C. auris clade III strains as described in Fig. 2e. Values in histogram plots depict median fluorescence intensity (MFI) and table
shows the mean fold-change in MFI ± SD for biological triplicates. d The relative intracellular azoffluxin abundance and e the relative intracellular FLC
abundance was quantified by LC-MS as described in Fig. 2b in Ci6684 (gray), B11221 (red), and B11222 (blue). Data are presented as mean ± SD of
technical triplicates. Significance of differences between azoffluxin and the combination treatment for each strain was determined by two-sided unpaired
Student’s t test, *p-value < 0.05, and ***p-value < 0.001 comparing. f Checkerboard assay as described in Fig. 1b using parental clade III isolate B12037 and
the strain with CDR1 deleted, in YPD medium. Relative growth was measured after 24 h as described in Fig. 1b (see color bar). The FICI for each
checkerboard is shown as described in Fig. 4. Source data are provided as a Source Data file.
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B11222, we observed a >6-fold increase in expression under
nearly all conditions tested compared to the clade I screening
strain Ci6684, suggesting that MDR1 is constitutively upregulated
in clade III isolates (Fig. 5a). In addition, despite the absence of
known TAC1 activating mutations in clade III isolates, we
observed increased expression of CDR1 in both clade III isolates
relative to Ci6684 under all treatment conditions except for the
drug combination (Figs. 5b and S3b). The lack of fluconazole
potentiation by azoffluxin in clade III isolates coupled with the
observation that efflux pump expression is high in these strains
suggested an efflux-independent fluconazole-resistance mechan-
ism in strains B11221 and B11222. To probe whether azoffluxin is
able to inhibit drug efflux activity in clade III strains, cellular
accumulation of Nile red, which is a substrate for both ABC and
MFS efflux pumps34, was measured in the absence and presence
of compound. Treatment with azoffluxin led to a 14.2-15-fold
increase in Nile red accumulation in B11221 and B11222
(Fig. 5c), which was not significantly different in magnitude from
the increase observed with the clade I screening isolate Ci6684
(Fig. 2e). Furthermore, LC-MS confirmed that azoffluxin accu-
mulated intracellularly in B11221 and B11222 (Fig. 5d), and levels
of intracellular fluconazole were significantly increased by com-
bination treatment compared to fluconazole alone (Fig. 5e). These
results suggest the lack of fluconazole potentiation by azoffluxin
in clade III isolates is not due to an inability of the compound to
inhibit efflux pumps, but rather that azole resistance in these
isolates is not due solely to efflux.
To investigate whether the Erg11V125A/F126L and/or Mrr1N647T
substitutions were likely responsible for resistance to the
fluconazole-enhancing effects of azoffluxin in clade III isolates,
we assessed the activity of azoffluxin against a clade III isolate
(B12037) that does not contain the Erg11 substitutions or the
Mrr1 substitution shared by most members of this clade7. While
more sensitive to fluconazole than other clade members at
baseline, this strain showed increased Nile red accumulation upon
treatment with azoffluxin (Fig. 5c) and showed potent synergistic
interaction between azoffluxin and fluconazole (Fig. 5f). Further-
more, when CDR1 was deleted in this background, it abolished
the synergistic activity (Fig. 5f), highlighting the importance of
Cdr1 for azole tolerance of this clade III isolate. Together, our
results suggest that substitutions in Erg11 and/or Mrr1 in B11222
and B11221 enable fluconazole resistance which is recalcitrant to
the effects of azoffluxin.
Azoffluxin displays activity against azole-resistant C. albicans.
Our studies so far supported a model in which azoffluxin inhibits
Cdr1-dependent fluconazole resistance in C. auris. Notably, our
initial findings suggested this compound combination was inef-
fective against C. albicans, C. glabrata, or S. cerevisiae (Fig. 1e),
indicating either species-specific differences in the manner by
which azoffluxin inhibits efflux pumps, or that efflux does not
play a role in the azole sensitivity of the strains we tested. To learn
whether azoffluxin had activity against strains of C. albicans in
which fluconazole resistance is mediated through enhanced
efflux, we assessed activity of the azoffluxin-fluconazole combi-
nation treatment against isolates from a patient who had received
intermittent therapy with fluconazole over the course of 2
years40,42,43. We observed no potentiation in the early clinical
isolate, CaCi-2 (Fig. 6a), which is reported to have no bona fide
resistance mutations, consistent with our finding of no poten-
tiation in an azole-sensitive laboratory strain, SN95 (Fig. 1e).
Interestingly, azoffluxin did potentiate fluconazole against the late
clinical isolate, CaCi-17, which possesses the substitutions A736V
in Tac1 and G947S in Mrr1 that lead to upregulation of multiple
efflux genes, in addition to gain-of-function mutations in the
transcription factor UPC2 that lead to overexpression of
Erg11R467K44,45. The ability of azoffluxin to potentiate fluconazole
in CaCi-17 was abolished upon deletion of CDR1 (Fig. 6a), similar
to what we observed in C. auris (Fig. 2f). Additionally, azoffluxin
was able to mildly potentiate fluconazole in three laboratory-
generated C. albicans strains with verified gain-of-function
mutations in TAC146, but not the sensitive parental strain
(Fig. 6b).
To confirm that azoffluxin inhibited efflux in C. albicans, we
assessed Nile red accumulation in CaCi-17 by flow cytometry. We
observed a similar increase in Nile red accumulation upon
azoffluxin treatment in both the parental CaCi-17 and the CaCi-
17 cdr1Δ/cdr1Δ strain (Fig. 6c). This suggests that while
azoffluxin is able to inhibit efflux pumps in C. albicans, Cdr1 is
either not the major Nile red transporter or other transporters are
able to compensate upon its deletion. Finally, to confirm that
combination treatment was blocking efflux and resulting in
increased fluconazole accumulation, we used LC-MS to measure
intracellular compound concentrations in SN95, which was
recalcitrant to the potentiation effects of azoffluxin (Fig. 1e),
and CaCi-17. Comparing combination treatment to that with
each compound alone, we only detected a significant increase in
fluconazole in CaCi-17 (Fig. 6d), while in both strains there was a
significant increase in azoffluxin (Fig. 6e). These data indicate
that azoffluxin blocks fluconazole efflux in a resistant clinical
isolate of C. albicans, increasing its sensitivity to fluconazole,
establishing bioactivity for azoffluxin beyond C. auris.
Combination treatment reduces fungal burden in vivo.
Encouraged by the intriguing mode of action we had uncovered,
we next assessed the therapeutic potential of combining azof-
fluxin with fluconazole. We first examined the ability of this
combination to rescue human kidney-derived (293T) cells when
infected with fungus47. 293T cells constitutively expressing firefly
luciferase as a reporter were either grown alone or in co-culture
with C. auris Ci6684 under various treatment conditions. Lumi-
nescence was used as an indicator of relative viable human cell
number. In the cases of solvent control, azoffluxin alone, or low
fluconazole, C. auris growth was unhindered, which resulted in
near complete human cell loss and an absence of luminescent
signal (Fig. 7a). However, with combination treatment (azoffluxin
and low fluconazole) we saw dramatic rescue of the human cells,
comparable to that achieved with a 16-fold higher concentration
of fluconazole alone (Fig. 7a). Notably, for 293T cells grown in the
absence of C. auris we saw no significant change in luciferase
signal under any treatment condition, indicating minimal cyto-
toxicity in vitro (Fig. 7a).
The same experimental design was performed in 24-well
plate format followed by Periodic-acid Schiff (PAS) staining of
polysaccharides to visualize effects of the various treatments on
both the fungal and human elements within the co-cultures.
Results supported findings obtained using the quantitative
assay. We observed extensive damage to the human cell
monolayer (stained pale purple) and sloughing in conjunction
with the presence of abundant C. auris (stained pink) in wells
exposed to azoffluxin alone or low fluconazole alone, compar-
able to the untreated co-culture. With combination treatment,
we observed an intact human cell monolayer which was similar
to the no fungus control, and scant fungal burden. In the high
fluconazole condition, some disruption of the human cell
monolayer was evident and fungal cells were readily apparent,
suggesting that high fluconazole was effective at reducing
fungal toxicity to the monolayer, but less effective than our
combination treatment in arresting fungal proliferation
(Fig. 7b).
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Justified by promising results in culture, the therapeutic
potential of azoffluxin was investigated in mice. First, we
assessed the stability of azoffluxin in mouse plasma by bio-
assay. Incubation of the compound in 100% mouse plasma for
1 h caused no decrease in azoffluxin potentiating activity.
Technical controls consisted of the experimental antifungal
gepinacin, which is readily inactivated by plasma48, and
caspofungin, a stable clinical antifungal (Fig. 7c). Next, a
single dose pharmacokinetic study was performed in mice to
inform design of appropriate regimens to assess tolerability
and efficacy. Following a 10-mg/kg bolus dose, the peak plasma
concentrations of azoffluxin achieved were well above those
required for azole-potentiating activity in vitro (>1 µg/mL) and
a half-life of ~ 2.6 h was defined (Fig. 7d). These findings
encouraged us to proceed with a repeated-dose tolerability





















Fig. 6 Azoffluxin enhances fluconazole (FLC) activity against azole-resistant C. albicans isolates. a Checkerboard assays as described in Fig. 1b were
performed in YPD with isolates of C. albicans. Strains CaCi-2 and CaCi-17 represent early and late clinical isolates in which FLC resistance evolved over
time. Growth was measured after 24 h using OD600 and normalized to a no-drug control well (see color bar). The FICI calculated for each checkerboard is
shown in the top right of each plot, with values <0.5 indicating synergy and >0.5 indicating no interaction. b Dose-response assays were conducted in YPD
medium with a C. albicans parental strain, and strains with gain of function mutations in TAC1 as indicated. FLC was titered in a 2-fold dilution on the x-axis
in the absence and presence of 50 µM azoffluxin. Growth was measured at 24 h using OD600 and normalized to a no-drug control well (see color bar).
c Flow cytometry was used to measure relative Nile red accumulation in C. albicans strains as described in Fig. 2e. Values in histogram plots depict median
fluorescence intensity (MFI) and table shows the mean fold-change in MFI ± SD for biological triplicates. d Relative intracellular levels of FLC and e relative
intracellular azoffluxin were measured by LC-MS in C. albicans strains SN95 (gray) and CaCi-17 (blue) after treatment (combo treatment: 6.25 µM
azoffluxin, 8 µg/mL FLC) for 1 h as described in Fig. 2b. Data are presented as mean ± SD of technical triplicates. Significance of differences was determined
by a two-sided unpaired Student’s t test comparing fluconazole alone to the combination, *p-value= 0.013 and **p-value > 0.011. Source data are provided
as a Source Data file.
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acute systemic toxicity after 4 days of treatment and 100%
survival after 21 days (Fig. 7e).
Finally, we evaluated the efficacy of azoffluxin in a well-
characterized mouse model of systemic C. auris infection49.
Immunocompromised mice were infected intravenously with the
azole-resistant clade IV isolate B11801, which we had confirmed
as susceptible to the fluconazole-potentiating effects of azoffluxin
(Fig. 8a). After four days of well-tolerated treatment, fluconazole
alone reduced kidney colony forming units (CFU) compared to
untreated mice, however, the addition of azoffluxin significantly
enhanced this activity (p-value < 0.001; Fig. 8b) compared to
either treatment alone. Unexpectedly, azoffluxin alone reduced
fungal burden by ~3-log10 CFU despite having shown no effect on
C. auris growth in vitro (Fig. 8). This surprising result suggests
that disruption of Cdr1 function by azoffluxin impairs C. auris



















Fig. 7 Preliminary characterization of the in vivo potential of azoffluxin. a Human cells (293T) expressing luciferase were grown in DMEM medium
overnight. 24 h later the indicated concentrations of compounds (• indicates concentrations of fluconazole (FLC) and azoffluxin used in combination
(combo) treatment) were added to cells alone (gray) or those infection with C. auris (blue). Co-cultures were incubated for 48 h at 37 °C followed by
measurement of luminescence. Data are presented as mean ± SD of quadruplicate wells. Significance of differences between 293T cells alone versus co-
cultures was determined by two-sided unpaired Student’s t test, (***p-value < 0.001 b Periodic-Acid Schiff (PAS) staining was used to visualize cells in co-
culture. Light purple staining identifies 293 T cells and the bright pink signal indicates C. auris. Scale bar represents 50 µm. c Plasma stability of azoffluxin
and relevant control compounds, gepinacin (GPN) and caspofungin (CF). Samples were incubated in 100%mouse plasma at either at 37 °C with 5.5% CO2
(maroon) or on ice (gray), or in the absence of serum in YPD (black). The drug-plasma mixtures were diluted 1:10 into C. auris Ci6684-inoculated YPD
medium. Relative growth was measured after 48 h at 30 °C by OD600. Data are presented as mean ± SD between technical triplicates, two-sided unpaired
Student’s t test was used to determine significance of difference between 37 °C with 5.5% CO2 condition compared to ice condition for each treatment,
***p-value < 0.001. d Plasma concentrations of azoffluxin in mice following intraperitoneal (IP) bolus administration of compound (10mg/kg). Azoffluxin
was quantitated in mouse blood (n= 3) by LC-MS/MS. Data are presented as mean ± SD of three mice. Pharmacokinetic properties shown in the table
below were evaluated using Analyst software (AB Sciex.) and the noncompartmental analysis tool in WinNonlin (Certara, Corp.). e Tolerability of
azoffluxin in mice was evaluated by treating neutropenic ICR (CD-1) mice with azoffluxin 10mg/kg IP twice daily for 4 days and monitoring the health and
survival of treated (blue) and untreated (black) mice (n= 5) for 21 days. Source data are provided as a Source Data file.
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demonstrated using genetic approaches in isolates of C.
glabrata50. Overall, azoffluxin displays antifungal activity
in vivo, further validating the concept of targeting resistance
mechanisms in combination with current antifungals to combat
C. auris infections.
Discussion
In this study, we leveraged a diversity-oriented chemical library to
discover CMLD012336 (azoffluxin) as a new compound that
enhances the susceptibility of resistant fungal pathogens to
diverse intracellularly acting antifungals. This compound inhibits
the activity of multidrug efflux transporters, most notably the
ABC transporter Cdr1. Enhanced multidrug efflux is a frequently
encountered and problematic mechanism of antimicrobial
resistance36,39,51–53. With the escalating problem of antifungal
resistance to public health, the ability of azoffluxin to inhibit drug
efflux in a non-toxic manner could have potential therapeutic
implications.
The 3,3-diarylated oxindole we named azoffluxin was identified
as an unexpected side product in a Lewis-acid mediated Friedel-
Crafts/Prins reaction process intended to generate spirocyclic
oxindoles54. 3,3-diarylated oxindoles are a subset of the medic-
inally “privileged” 3,3-disubstituted oxindole class, which have a
rich history of reported biological activities. For example, the
diphenolic oxindole oxyphenisatin and other 3,3-diarylated oxi-
ndoles have been widely reported to inhibit the growth of diverse
cancer cell lines, in many cases the activity being ascribed to
inhibition of eIF2α-mediated translation initiation55,56. Another
3,3-diarylated oxindole BHPI, has been reported to act as a non-
classical agonist of human estrogen receptor α and was recently
shown to deplete intracellular ATP in estrogen receptor-positive
cancer cells, thereby disrupting ATP-dependent ABC transporter-
mediated drug efflux57. Whether BHPI might directly inhibit
human or fungal ABC transporters is unknown. Other 3,3-bisaryl
oxindoles have been reported as mineralocorticoid receptor
antagonists58, as well as antioxidants59. Although azoffluxin falls
into the general class of 3,3-disubstituted oxindoles, its specific
substituents impart structurally distinct features to the com-
pound. In addition to differences at the level of chemical struc-
ture, divergence in the processes reported to be impacted by other
class members between mammalian and fungal cells, and azof-
fluxin’s lack of cytotoxicity to human cells and good tolerability in
mice make it unlikely that azoffluxin operates through the
mechanisms previously described for other 3,3-disubstituted
oxindoles.
Using azoffluxin as a chemical probe, we found that C. auris
strains belonging to clades I, II, and IV were sensitized to flu-
conazole, implicating efflux as a major factor contributing to their
high azole-resistance. Indeed, inhibition of efflux in these strains
markedly reduced their fluconazole resistance, despite the pre-
sence of Erg11 alterations, most notably Erg11Y132F and
Erg11K143R that have been reported to cause a >4-fold increase in
azole MIC16. Furthermore, azoffluxin reduced azole resistance of
a C. albicans strain harboring numerous resistance-conferring
mutations in genes such as ERG11, TAC1, MDR1, and UPC244,45.
Deletion of CDR1 in specific strains of C. auris and C. albicans
abolished azoffluxin-mediated potentiation. In contrast, we did
not observe azoffluxin-mediated fluconazole potentiation in the
more divergent fungal species C. glabrata and S. cerevisiae. One
explanation would be that Pdr5, the homologous efflux pump in
these species, is not inhibited by azoffluxin, which is plausible
given the relatively low 56% sequence identity between Cdr1 and
Pdr560. Alternatively, efflux may not be a driving factor in
determining the fluconazole sensitivity of the strains used as
representatives of these species.
Within C. auris, we found that isolates from clade III were
distinct in their lack of susceptibility to the fluconazole-sensitizing
effect of azoffluxin. Clade III isolates often express an Erg11
variant with V125A/F126L substitutions and harbor a unique
substitution in Mrr1 (N647T), which likely leads to upregulation
of the MFS pump Mdr17. Unlike clade I and IV, this clade does
not possess candidate drug-resistance substitutions in Tac1b21.
While we confirmed upregulation ofMDR1 and CDR1 in clade III
isolates compared to clade I, azoffluxin treatment of these strains
still increased accumulation of fluconazole, and Nile red which is
a substrate of both Mdr1 and Cdr1. The mechanism(s) under-
lying this observation is unclear but include the possibility that
azoffluxin inhibits Mdr1 as well as Cdr1. Alternatively, inhibition
of Cdr1 in these strains might be sufficient to increase compound
accumulation despite Mdr1 upregulation, or azoffluxin is able to
inhibit the function of yet other efflux pumps for which these
compounds are also a substrate34. Irrespective of their mechan-
ism, our findings and the observation that azoffluxin synergized








Fig. 8 Azoffluxin increases the antifungal activity of fluconazole (FLC) in mice. a Checkerboard assays were performed as described in Fig. 1b with C.
auris clade IV isolate B11801. Relative growth was measured after 24 h using OD600 and normalized to no-drug control wells (see color bar). The FICI is
shown in the top right of each plot, with values <0.5 indicating synergy. b Kidney fungal burden (CFU) in mice from each treatment group that had been
infected with C. auris B11801. Input is the CFU recovered in an aliquot of the fungal suspension used to inoculate mice. All other values are the CFU
recovered from kidney homogenates after 4 days of treatment. Fluconazole was administered at 32mg/kg intraperitoneally twice daily and azoffluxin at 10
mg/kg subcutaneously four-times daily. Data are presented as mean ± SD of n= 3 mice per treatment group. Experiment was performed in two
independent replicates (purple and blue). The significance of differences between combination treatment and treatment with each compound alone was
determined for each replicate by two-sided unpaired Student’s t test, **p-value < 0.01 and ***p-value < 0.001. Source data are provided as a Source
Data file.
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carry the Erg11V125A/F126L or Mrr1N647T substitutions suggest
that one or more of these resistance-conferring mutations is
responsible for the inability of azoffluxin to potentiate fluconazole
activity against most clade III isolates. In light of a previous report
that Mdr1 does not play a role in fluconazole resistance of clade I
isolates20 and our finding that azoffluxin enhanced fluconazole
accumulation in clade III isolates, it is likely that the impact of
Mdr1 upregulation on azole resistance in clade III strains is
negligible. Rather, the specific Erg11V125A/F126L mutant target
protein in most clade III strains is likely the dominant determi-
nant of their fluconazole resistance and would explain the
inability of an efflux pump inhibitor such as azoffluxin to restore
azole sensitivity.
Efflux is regulated by complex and highly interconnected
genetic circuitry. Recent analyses of S. cerevisiae genetic interac-
tion networks show that perturbation through deletion of specific
ABC transporter genes can paradoxically lead to an increase in
azole resistance61. This response was mediated, at least in part by
compensatory upregulation of PDR5 expression, as deletion of
PDR5 restored fluconazole sensitivity61. We find that expression
of efflux genes such as CDR1 and CDR4-1 were upregulated in C.
auris in response to azoffluxin, while genes such as SNQ2-2 were
downregulated. This pattern highlights the complex connectivity
of the efflux network as well as the potential contribution of
general stress responses to efflux pump expression. Regardless,
this upregulation did not preclude the ability to sensitize cells to
fluconazole. The robust activity of azoffluxin despite the com-
pensatory upregulation of efflux genes reflects the strong
dependence of high level fluconazole-resistance on Cdr120,61,62.
Consistent with this dependence, the highly resistant C. albicans
clinical isolate CaCi-17 was susceptible to azoffluxin-fluconazole
combination treatment. In contrast, azoffluxin had no impact on
azole sensitivity of the earlier clinical isolate CaCi-2, which pos-
sesses no bona fide mutations and is far more susceptible to
fluconazole. Such insights underscore the value of azoffluxin as a
chemical probe to discern the relative role of efflux in mediating
antifungal drug resistance across diverse fungal pathogens.
From a therapeutic perspective, utilizing a chemical combina-
tion in which one compound targets an essential process and the
other disables a major resistance mechanism provides an attrac-
tive strategy that has been explored for both antimicrobial and
cancer treatment39,52,63–66. In the case of efflux inhibitors, not
only does this strategy enhance the efficacy of the other com-
pound, but if applied early in the course of intervention, it can
also reduce the rate at which resistance emerges39,67. Despite the
conceptual appeal, no efflux inhibitor combination therapies have
proven effective in patients52. This failure in clinical translation
has largely been due to host toxicity, off target effects, and/or the
poor pharmacokinetics that have plagued current efflux inhibitors
such as verapamil, cyclosporin A, and valspodar39,66. In this
study, we found azoffluxin to be very well tolerated both in cul-
ture and in mice. As well, azoffluxin significantly enhanced flu-
conazole activity in an immunocompromised mouse model of
invasive C. auris infection, and reduced fungal burden by ~1000-
fold even as a single agent, consistent with the role of Cdr1 in
virulence of C. glabrata50.
An additional distinct challenge to the efficacy of efflux inhi-
bitors is the emergence of target-based and other resistance
mechanisms that can render efflux a less important factor con-
tributing to the overall resistance level of a fungal pathogen52.
Encouragingly, azoffluxin remains able to sensitize azole-resistant
Candida strains despite the presence of target-based resistance
mechanisms. While overall results are encouraging, they are
clearly discovery-phase in nature and will require further devel-
opment for translation to clinical application. As the number of
drug-resistant infections continues to rise, there remains a need
to understand the relative contribution of different resistance
mechanisms to the diminishing efficacy of our limited antifungal
armamentarium and to design new resistance-evasive treatment
strategies.
Methods
Strain construction. All strains, plasmids, and oligonucleotides used in this study
are listed in Supplementary Information.
CauLC6410: C. auris Ci6684 cdr4-1△::NAT. The C. auris strain with CDR4-1
(B9J08_000479) deleted was constructed using homologous recombination and an
electroporation transformation approach35. Approximately 1 kb of sequence
homology upstream of CDR4-1 was amplified using primers oLC8164/oLC8165
and ~1 kb of homology downstream of CDR4-1 was amplified with oLC8166/
oLC8167. The interior primer of each set contained 40 bp homology to a nour-
seothricin (NAT) resistance marker from pLC1049, which was amplified with
primers oLC6296/oLC6304. Using fusion PCR with nested primers oLC8168/
oLC8169, the NAT cassette and CDR4-1 homology regions were combined into a
single DNA fragment. This PCR product was ethanol precipitated. C. auris
CaLC5083 cells were prepared by growing in 50 mL YPD medium to an OD600 of
1.6–2.2. Cells were pelleted for 5 min at 3000×g, then subcultured for 1 h in 10 mL
10 mM Tris-HCl (Bioshop), and 1 mM EDTA (Bioshop) in ddH2O (1x TE buffer)
and 0.1 M Lithium Acetate (Sigma). In all, 250 µL of 1 M DTT was added to the
culture for 30 min. Cells were washed twice in cold ddH2O followed by a wash in
cold 1M sorbitol (Bioshop). In all, 3 μg of DNA was electroporated into 40 µL
CaLC5083 cell suspension in a 2-mm electroporation cuvette (VWR) with the
following settings on a BTX ECM830 electroporator: 1.8 kV, 200Ω, 25 µF and
outgrown in YPD medium for 4 h at 30 °C. Transformants were plated on YPD
plates containing 150 μg/mL NAT. Colonies were patched and genotyped for
integration of the deletion construct (oLC8164/oLC6308 and oLC274/oLC8167)
and for the absence of the wild-type allele (oLC8052/oLC8053).
CaLC5447: C. albicans CaCi-17 cdr1△/cdr1△. Both alleles of CDR1
(C3_05220W) were deleted by a transient CRISPR method68. The guide construct
was made of two components from pLC1081: the SNR52 promoter amplified with
the universal primer oLC6929 and guide specific primer oLC6966, and the guide
scaffold and terminator amplified with the guide specific primer oLC6967 and
universal primer oLC6927. The fusion construct was PCR amplified with the
universal nested primers oLC6928/olC692969. Repair template was digested from
pLC1083 by ApaI (NEB) and SacI (NEB). Gene deletion was verified by the absence
of the CDR1 specific amplicon with oLC6968/oCL696969.
CaLC5589: C. albicans SN152 TAC1/TAC1. Stepwise insertion of wild-type TAC1
back into the tac1△/tac1△ deletion mutant CaLC425570 to match gain-of-function
strains below. oLC1096 was digested by BamHI (NEB) and SacII (NEB) and used
to transform CaLC4255. NAT resistant transformants was further triaged by a
histidine auxotrophy. Re-introduction of the TAC1 ORF was verified by the pre-
sence of the oLC7041 and oLC7042 amplicon. Subsequently, pLC1092 was digested
by BamHI and SacII and used in a second transformation. Transformants proto-
trophic for histidine were further selected for NAT resistance.
CaLC5591: C. albicans SN152 Tac1M677△/Tac1M677△. Stepwise insertion of a
TAC1A2029-G2031△ (Tac1M677△ allele) into the tac1△/ tac1△ deletion mutant
CaLC4255. oLC1097 was digested by BamHI and SacII and used to transform
CaLC4255. NAT resistant transformants was further triaged by a histidine auxo-
trophy. Re-introduction of the TAC1A2029-G2031△ ORF was verified by the presence
of the oLC7041 and oLC7042 amplicon. Subsequently, pLC1093 was digested by
BamHI and SacII and used in a second transformation. Transformants proto-
trophic for histidine were further selected for NAT resistance.
CaLC5593: C. albicans SN152 Tac1 N972D/Tac1 N972D. Stepwise insertion of a
TAC1A2914G (Tac1N972D allele) into the tac1△/ tac1△ deletion mutant CaLC4255.
oLC1098 was digested by BamHI and SacII and used to transform CaLC4255. NAT
resistant transformants was further triaged by a histidine auxotrophy. Re-
introduction of the TAC1A2914G ORF was verified by the presence of the oLC7041
and oLC7042 amplicon. Subsequently, pLC1094 was digested by BamHI and SacII
and used in a second transformation. Transformants prototrophic for histidine
were further selected for NAT resistance.
CaLC5595: C. albicans SN152 Tac1N977D/Tac1N977D. Stepwise insertion of a
TAC1A2929G (Tac1N977D allele) into the tac1△/ tac1△ deletion mutant CaLC4255.
oLC1099 was digested by BamHI and SacII and used to transform CaLC4255. NAT
resistant transformants was further triaged by a histidine auxotrophy. Re-
introduction of the TAC1A2929G ORF was verified by the presence of the oLC7041
and oLC7042 amplicon. Subsequently, pLC1095 was digested by BamHI and SacII
and used in a second transformation.
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Transformants prototrophic for histidine were further selected for NAT
resistance.
CauLC6750: C. auris B12037 cdr1△::NAT. To delete CDR1 (B9J08_000164) in C.
auris B12037 a homologous recombination and electroporation transformation
approach was used35. Approximately 1 kb of sequence homology upstream of
CDR1 was amplified using primers oLC6020/oLC6305 and ~1 kb of homology
downstream was amplified with oLC6306/oLC6025. The interior primer of each set
contained 40 bp homology to a nourseothricin (NAT) resistance marker from
pLC1049, which was amplified with primers oLC6296/oLC6304. Using fusion PCR
with nested primers oLC6024/oLC6307, the NAT cassette and CDR1 homology
regions were combined into a single DNA fragment. This PCR product was ethanol
precipitated, 5 μg of DNA was electroporated into CauLC6554, and transformants
were plated on YPD plates containing 150 μg/mL NAT. Colonies were patched and
genotyped for integration of the deletion construct (oLC6221/oLC6308 and
oLC274/oLC6023) and for the absence of the wild-type allele (oLC6231/oLC6169).
Statistics and reproducibility. All data presented in this study are derived from
two biological experiments in which both results agreed, and data shown in the
figures are from technical replicates from a single biological replicate, representa-
tive of both, unless otherwise stated. All statistical analysis was performed by a two-
sided Student’s t test in Microsoft Excel (version 16.41) unless otherwise stated.
Culture conditions. All fungal strains were stored in 25% glycerol in YPD medium
(YPD: 1% yeast extract, 2% peptone, and 2% D-glucose) and maintained at −80 °C.
Strains were grown in either YPD or RPMI medium (10.4 g/L RPMI-1640, 3.5%
MOPS, 2% D-glucose, supplemented with an additional 5 mg/mL histidine as
required, pH 7). The mammalian cell line of human embryonic kidney 293T cells
was stored in glycerol and cultured in DMEM medium (Sigma) with 10% fetal
bovine serum (FBS; Gibco).
BU-CMD library screen. A set of 2,454 compounds from the Boston University
Center for Molecular Discovery (BU-CMD) library were used to identify com-
pounds that enhance fluconazole activity against C. auris. All compounds were
dissolved in DMSO (dimethyl sulfoxide; Sigma) at 5 mM. RPMI medium alone or
containing 128 μg/mL fluconazole (MIC > 256 μg/mL; Sequoia Research Products)
was inoculated with ~1 × 103 cells/mL of C. auris (VPCI 673/P/12) from a satu-
rated overnight culture. Both types of media were dispensed at 100 μL per well into
96-well, flat bottom, microtiter plates (Sarstedt). In total, 1 μL of DMSO-solubilized
compound from the library was added into each well to a final concentration of 50
μM. Cells were incubated for 48 h at 30 °C and OD600 was read (Molecular Devices
SpectraMax Plus 384). After the initial screen, all secondary chemical susceptibility
assays were performed on fresh sample aliquots that were first assessed for purity
by UPLC-MS-ELSD analysis.
Chemical susceptibility assays. Compound potency was assessed alone by dose-
response assays or in combination with another compound by dose-response
matrixes in 96-well plates, or 384-well, flat bottom, microtiter plates (Corning)71.
Plates were incubated at 30 °C for the indicated time period. Growth was quantified
by measuring OD600 and corrected for medium background. All strains were
assessed in biological duplicate experiments with technical duplicates. Growth was
normalized to untreated controls and plotted as a heat map using Java TreeView
(version 1.1.6r4). For dose-response matrixes fractional inhibitory concentration
index at 90% growth inhibition (FICI90) was calculated using the formula:
MICDrugACombo
MICDrugAAlone
þ MICDrug BComboMICDrug BAlone
 
30. The fluconazole Etest susceptibility assay was per-
formed by plating 200 μL of 5 × 106 cells/mL on YPD agar (1%) plates with either
50 μM azoffluxin or containing DMSO35. Etest strips (bioMérieux) were placed on
top after drying and plates were incubated for 24 h at 30 °C and imaged. Etest
susceptibility assays were performed in biological duplicate.
BU-CMD hit compounds were newly supplied and dissolved in DMSO.
Gepinacin (Toronto Research Chemicals), cerulenin (Cayman Chemical
Company), cycloheximide (BioShop), caspofungin (generously provided by
Merck), and amphotericin B (Sigma) were dissolved in DMSO. Fluconazole was
dissolved in sterile ddH2O or DMSO.
Chemical synthesis
General methods. 1H NMR spectra were recorded at 400 or 500MHz at ambient
temperature unless otherwise stated. 13C NMR spectra were recorded at 100 or 125
MHz at ambient temperature unless otherwise stated. Chemical shifts are reported
in parts per million. Data for 1H NMR are reported as follows: chemical shift,
multiplicity (app= apparent, br= broad, s= singlet, d= doublet, t= triplet, q=
quartet, sxt= sextet, m=multiplet, ovrlp= overlap), coupling constants, and
integration. All 13C NMR spectra were recorded with complete proton decoupling.
Analytical thin layer chromatography was performed using 0.25 mm silica gel 60-F
plates. Flash chromatography was performed using 200–400 mesh silica gel (Sor-
bent Technologies, Inc.) or prepack column (SI-HC, puriFlash) by Interchim.
Isolated yields refer to chromatographically and spectroscopically pure
compounds, unless otherwise stated. Analytical LC-MS experiments were per-
formed using a Waters Acquity UPLC (ultra-performance liquid chromatography)
with a binary solvent manager, SQ mass spectrometer, Waters 2996 PDA (pho-
todiode array) detector and evaporative light scattering detector (ELSD).
All compounds tested in biological assays were determined to be >95% pure by
UPLC-MS-ELSD analysis. For validation, the screening hit CMLD012336 was
resynthesized via Lewis-acid mediated condensation of 6-fluoro-3,3-
dimethoxyindolin-2-one and (R)-1-(benzo[d][1,3]dioxol-5-yloxy)-4-methylpent-4-
en-2-ol.
6-Fluoro-3,3-dimethoxyindolin-2-one. To a flame-dried 100 mL round bottomed
flask equipped with a reflux condenser under an atmosphere of N2 was added 6-
fluoroisatin (1.0 g, 6.06 mmol), trimethylorthoformate (729 µL, 6.66 mmol), and
methanol (30 mL). p-Toluenesulfonic acid monohydrate (172.8 mg, 0.908 mmol)
was added and the reaction was heated to reflux for 5.5 h. After cooling to ambient
temperature, the reaction was diluted with diethyl ether and neutralized with a
saturated solution of sodium bicarbonate. The organic layer was separated, and the
aqueous layer was extracted twice with diethyl ether. The combined organics were
dried over sodium sulfate, filtered, and concentrated under reduced pressure. The
residue was taken up in diethyl ether, filtered over a pad of celite/Na2SO4, and
concentrated to give a yellow solid. The crude yellow solid was purified flash
column chromatography (SiO2, gradient elution 1→ 7% methanol/dichlor-
omethane, Interchim PuriFlash 450) to give product 6-fluoro-3,3-dimethox-
yindolin-2-one (1.06 g; 82.8% yield). LCMS m/z [M-OMe]+ 180. 1H NMR (400
MHz, CD3COCD3) δ 9.57 (br s, 1H), 7.44 (dd, J= 8.21, 5.47, 1H), 6.79 (m, 1H),
6.72 (dd, J= 8.99, 2.34, 1H), 3.48 (s, 6H). 13C NMR (126MHz, CD3COCD3) δ
173.1, 166.4, 164.5, 145.0, 144.9, 128.3, 109.3, 109.1, 100.1, 99.9, 51.2. HRMS [M
+Na]+ calcd. for C10H10FNO3Na 234.0545, found 234.0542.
(R)-1-(Benzo[d][1,3]dioxol-5-yloxy)-4-methylpent-4-en-2-ol. In a flame-dried 50
mL round bottom flask under an atmosphere N2 was stirred a suspension of copper
iodide (65.4 mg, 0.21 mmol) in THF (2 mL) cooled to −40 °C using an acetonitrile/
CO2 bath. To this suspension was added isopropenylmagnesium bromide (0.5 M in
THF, 6.18 mL). The reaction was stirred at −40 °C for 35 min. Next, a solution of
5-[[(2 R)-oxiran-2-yl]methoxy]-1,3-benzodioxole (400 mg, 2.06 mmol) in THF was
added dropwise. The reaction was stirred at −40 °C for 150 min. The brown
colored mixture was quenched at −40 °C by dropwise addition of saturated aqu-
eous ammonium chloride (0.4 mL). The product mixture was then filtered over a
pad of Celite/SiO2/Na2SO4. This pad was eluted with 60% ethyl acetate in hexanes
(100 mL) and ethyl acetate (60 mL) to afford the desired product (493 mg) as a
colorless oil in quantitative yield. 1H NMR (400MHz, CDCl3) δ 6.71 (d, J= 8.6 Hz,
1H), 6.53 (d, J= 2.7, 1H), 6.35 (dd, J= 8.4, 2.4, 1H), 5.93 (s, 2H), 4.91 (s, 1H), 4.85
(s, 1H), 4.14 (m, 1H), 3.92 (dd, J= 9.3, 3.7, 1H), 3.83 (dd, J= 9.3, 7.1, 1H), 2.32 (d,
J= 6.6, 2H), 1.81 (s, 3H). 13C NMR (126MHz, CDCl3) δ 154.1, 148.3, 141.7, 113.7,
107.9, 105.8, 101.2, 98.2, 72.8, 67.8, 41.9, 22.5. HRMS [M+Na]+ calcd. for
C13H16O4Na 259.0946, found 259.0944.
(6-Fluoro-3,3-bis(6-(((R)-2-hydroxy-4-methylpent-4-en-1-yl)oxy)benzo[d][1,3]
dioxol-5-yl)indolin-2-one (azoffluxin; CMLD012336). In a two dram vial under
N2 was stirred 6-fluoro-3,3-dimethoxy-indolin-2-one (70 mg, 0.33 mmol) and (R)-
1-(benzo[d][1,3]dioxol-5-yloxy)-4-methylpent-4-en-2-ol (170 mg, 0.72 mmol) in
dichloromethane (4.2 mL). To this reaction was added magnesium sulfate (325 mg,
2.70 mmol). The reaction was cooled to 0 °C in an ice bath and scandium(III)
triflate (400 mg, 0.81 mmol) was added. The reaction was allowed to slowly warm
to room temperature. After stirring at room temperature overnight, the reaction
was filtered through a pad of Celite eluting with dichloromethane. After con-
centration in vacuo, the crude residue was purified by flash column chromato-
graphy (SiO2, gradient elution 15–45% acetone in hexanes, Interchim PuriFlash
450) to afford azoffluxin (84 mg, 40.9% yield). LCMS m/z [M+H]+ 620. At
ambient temperature, azoffluxin exhibits multiple sets of broadened 1H and 13C
NMR peaks due to rotamers by restricted rotation of the biaryl system. NMR peaks
were found to coalesce upon heating to 150 °C. NMR chemical shifts at both
temperatures are reported.
1H NMR (DMSO-d6, 400 MHz, 25 °C) δ 10.60 (br s, 1 H), 7.35-7.17 (m, 1H),
6.77-6.72 (m, 2H), 6.67-6.55 (m, 2H), 6.48 (br. s, 0.5 H), 6.14 (br. d, J= 12.5 Hz,
1H), 5.95-5.90 (m, 2H), 5.88-5.84 (m, 2H), 4.67-4.63 (m, 2H), 4.57-4.46 (m, 2H),
3.78-3.38 (m, 5H), 3.30-3.33 (m, 1H), 1.95-1.72 (m, 4H), 1.65-1.55 (m, 6H); 13C
NMR (DMSO-d6, 100 MHz, 25 °C) δ 180.0, 179.8, 163.5, 163.3, 161.0, 160.9, 153.0,
152.5, 151.9, 151.6, 147.7, 147.5, 147.23, 147.17, 143.2, 143.0, 142.95, 141.2, 141.0,
140.8, 130.8, 130.3, 127.2, 127.1, 126.8, 126.6, 121.1, 120.7, 112.6, 112.3, 109.2,
108.25, 108.2, 108.0, 107.8, 107.6, 101.7, 101.6, 97.9, 97.6, 97.2, 97.0, 96.95, 96.8,
74.0, 73.5, 73.1, 72.9, 67.5, 67.4, 67.3, 67.0, 59.3, 59.0, 42.2, 42.0, 41.8, 41.6, 23.13,
23.08, 23.05, 22.97. 1H NMR (DMSO-d6, 400 MHz, 150 °C) δ 9.94 (br. s, 1H), 7.21
(dd, J= 7.8, 6.3 Hz, 1H), 6.69-6.58 (m, 5H), 6.41 (br. s, 2H), 5.88 (s, 4H), 4.75-4.71
(m, 2H), 4.68 (br. s, 1H), 4.65 (br. s, 1H), 3.76-3.57 (m, 6H), 2.07-1.83 (m, 4H),
1.70 (s, 3H), 1.68 (s, 3H); 13C NMR (DMSO-d6, 100 MHz, 150 °C) δ 179.5, 162.6
(d, 1JC-F= 241 Hz), 152.7, 147.6, 143.5, 143.4, 143.1, 142.0, 130.7, 127.2, 127.1,
121.8, 112.1, 112.0, 108.8, 107.8, 107.5, 101.5, 97.8, 97.6, 97.2, 74.2, 68.3, 68.1, 59.6,
42.2, 41.4, 22.90, 22.85. HRMS [M+H]+ calcd. for C34H35FNO9 620.2296, found
620.2294.
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Extraction and quantification of sterols. To quantify the abundance of sterols in
C. auris the targeted metabolomics profiling protocol established by Hoepfner
et al.13 in S. cerevisiae was used. Cells were subcultured to an OD600 of 0.1 in 10 mL
of RPMI supplemented with the indicated compound concentration for 18 h with
agitation. After incubation growth (OD600) was normalized and cell pellets washed
and resuspended in 100 µL of PBS. Cell suspension was treated with 1 mL
methanol/CHCl3 (2:1 v/v) supplemented with 0.01% w/v butylated hydroxytoluene.
Acid washed glass beads were added to each sample and they were vortexed for 10
min. Samples were pelleted by centrifugation for 5 min at 16,000×g. Transferring
the supernatant to a new vial, 400 μL 50 mM citric acid in H2O, and 600 μL CHCl3
was added and vortexed for 10 min. Samples were again centrifuged for 5 min at
16,000×g. The organic phase was collected and dried. For LC-MS analysis, samples
were resuspended in ethanol with cholesterol included as an internal standard.
Samples were separated on Acquity UPLC BEH C18 column (1.7 μm, 2.1 × 50 mm)
using the Acquity UPLC I-Class coupled to a Xevo G2-S QToF equipped with an
APCI source (Waters). Chromatographic methods were adopted from Hoepfner
et al. as well as the selective reaction monitoring mass transitions specific for each
sterol in subsequent quantification steps. TargetLynx (Waters; version 4.1) was
used for peak finding, smoothing and area calculations. All samples were run in
biological duplicate and technical triplicate, and a representative replicate was
plotted in GraphPad Prism (version 8.4.2).
Intracellular fluconazole and azoffluxin detection. C. auris was subcultured
from overnight cultures at a starting OD600 of 0.4 in 5 mL of YPD in the presence
of the indicated compound concentration for 1 h with agitation. Cells were then
transferred to falcon tubes and pelleted at 3000×g for 5 min at 4 °C. Media was
removed, and cells were washed with 5 mL of cold PBS three times with cen-
trifugation of 2000×g for 5 min in between. Cells were resuspended in 1 mL cold
PBS, flash frozen in liquid nitrogen, and stored at −80 °C overnight. The following
day, cells were thawed on ice, 25 μL of 6 N NaOH was added to each falcon tube,
and samples were vortexed for 15 s. In all, 500 μL of 10 mM sodium phosphate (pH
6.0) was added to each sample followed by vortexing for 15 s. Compounds were
extracted with 5 mL of CH2Cl2 and vortexed for 5 min, followed by centrifugation
for 10 min at 4000×g at 4 °C. The organic phase was collected and dried. Before
subsequent LC-MS analysis, samples were resuspended in 50 μL MeCN:H2O. The
resuspended cell extracts (10 µl) were separated on an Acquity UPLC BEH C18
column (1.7 μm, 2.1 × 50 mm) using the Acquity UPLC I-Class coupled to a Xevo
G2-S QToF equipped with an electrospray ionization (ESI) source. Chromato-
graphy followed a gradient method (A: water+ 0.1% (v/v) formic acid, B: MeCN +
0.1% (v/v) formic acid | 0–9 min: 10% B to 95% B at 0.125 µL min−1). Both
fluconazole and azoffluxin were detected using selected reaction monitoring mass
transitions 307.110 [M+H]+→ 220.0685 and 602.227 [M-H2O+H]+→ 286.0515,
respectively. TargetLynx (Waters) was used for peak finding, smoothing and area
calculations. All samples were run in biological duplicate and technical triplicate
and a representative replicate was plotted in GraphPad Prism.
Quantitative real-time-PCR. To determine changes in efflux gene expression,
strains were subcultured from a saturated overnight culture at an OD600 0.1 in YPD
for 3 h in the presence of compound as indicated. Cells were then pelleted at
3000×g at 4 °C, washed with cold PBS, flash frozen with liquid nitrogen, and stored
at −80 °C. Cells were lysed by bead beating 4x for 30 s with 1 min on ice in
between. RNA was extracted from lysed cells using the QIAGEN RNeasy kit and
DNase treated using the QIAGEN RNase free DNAase Set. Complementary DNA
synthesis was performed using the iScript cDNA Synthesis Kit (Bio-Rad). Quan-
titative real-time-PCR (RT-qPCR) was performed using in a 384-well plate, with a
10 μL reaction volume using Fast SYBR Green Master Mix (Applied Biosystems)
and the BioRad CFX-384 Real Time System with the following cycling conditions:
95 °C for 3 min, then 95 °C for 10 s and 60 °C for 30 s, for 40 cycles. The melt curve
was completed with the following cycle conditions: 95 °C for 10 s and 65 °C for 10 s
with an increase of 0.5 °C per cycle up to 95 °C. Reactions were performed in
technical triplicate using the primer pairs: CDR1 (oLC6125/oLC6126), MDR1
(oLC8050/oLC8051), CDR4-1 (oLC8052/oLC8053), CDR4-2 (oLC8054/oLC8055),
SNQ2-1 (oLC8060/oLC8057), SNQ2-2 (oLC8058/oLC8059), and normalized to the
house keeping genes ACT1 (oLC5727/oLC5728) and GPD1 (oLC5729/oLC5730).
Primer sequences are included in Supplementary Information. Data were analyzed
using the BioRad CFX Manager 3.1. Error bars depict standard error of the means
of technical triplicates, representing the data from one of two biological replicates.
Nile red accumulation assay. Cellular efflux was determined by measuring Nile
red accumulation34. Cells were subcultured from an OD600 0.1 in YPD for 4 h until
exponential phase was reached. For cells treated with azoffluxin, 50 μM was added
for 10 min prior to a 20-min incubation of all stained cells with 7 μM (3.5 mM in
DMSO stock) of Nile red (Sigma). Cells were then pelleted for 1 min at 3000×g and
resuspended in PBS. To quantify fluorescence, a CytoFlex Flow Cytometer
(Beckman Coulter) was used. Cells were added to flat bottom, transparent, 96-well
plate (Beckman Coulter). Each sample was run using the CytExpert Software
(version 2.4) until ~20,000 events had been recorded. Populations were gated to
exclude debris and doublets, and the median PE value was taken for each sample
(Fig. S3 and Supplementary Data 1). To visualize samples, PBS cell suspensions
were imaged by differential interference contrast (DIC) microscopy and the DsRed
channel on a Zeiss Axio Imager.MI (Carl Zeiss) at the same exposure time. All
experiments were performed in biological triplicate and a Student’s t test was used
to compare significant differences in the fold-change upon azoffluxin treatment
between strains when indicated.
Co-culture experiments. To assess the ability of azoffluxin to rescue mammalian
cell growth in co-culture experiments, 20 μL of 293 T cells were seeded at 1 × 105
cells/mL in DMEM media containing 10% FBS and incubated overnight at 37 °C in
5.5% CO2. The following day 20 μL of DMEM inoculated with 2.5 × 103 cells/mL
exponential phase C. auris cells was added to the wells. A Tecan D300e compound
dispenser was used to add DMSO-based compounds to each well at the indicated
final concentrations. Co-cultures were incubated for 48 h at 37 °C in 5.5% CO2. The
mammalian cell growth was measured by replacing the media with 20 μL PBS, and
adding 20 μL Titer-glow (Promega) to each well, incubating for 10 min, and
reading luminescence on a Tecan Infinite 200 Pro. All experiments were performed
in technical quadruplicate and biological duplicate and plotted in GraphPad Prism.
The cellular glycoproteins were stained in co-culture experiments using a
periodic-acid Schiff (PAS) staining kit (Sigma) as per manufacturer’s instructions.
Mammalian 293 T cells were seeded at 5 × 104 cells/well for 24 h in six-well plates
(Corning). In all, 2.5 × 103 exponential phase C. auris cells were added to
mammalian cells followed by indicated drug or solvent concentrations. Plates were
incubated for 48 h at 37 °C. Cultures were fixed with 4% formaldehyde (BioShop)
in medium overnight, fixative was removed, and the plate was dried. Fixed cells
were then hydrated with 1 mL ddH2O and this was removed from each well. In
total, 1 mL PAS solution was added and cells were incubated for 5 min, followed by
removal and 2x washes with ddH2O by pipetting. In all, 1 mL Schiff’s reagent was
added, and plates were incubated for 15 min. The cells were then thoroughly rinsed
for 5 min with ddH2O. In all, 1 mL hematoxylin was applied for 3 min and cell
were rinsed again. Cells were allowed to dry and were then imaged. Experiments
were performed in biological duplicate, with one representative image being shown.
Plasma stability assay. To assess the ability of azoffluxin to retain activity after
exposure to mouse serum, a 10x concentration of azoffluxin was incubated for 1 h in
100% mouse plasma in sodium citrate buffer (Cedarlane, CL8001). This was incubated
along with the control compounds gepinacin, which is known to be metabolized by
serum, and caspofungin, which is not metabolized by serum. Compounds were
incubated at either at 37 °C or on ice, or in the absence of serum in a YPD medium
control at 37 °C. 10 μL of the mixture was then added to 90 μL of YPD inoculated with
C. auris Ci6684 to a final concentration of ~1 × 103 cells/mL in a 96-well plate. Plates
were incubated at 30 °C and growth was measured after 48 h by OD600. All experi-
ments were performed in technical triplicate and biological duplicate.
Mouse studies. The pharmacokinetics of azoffluxin in mice were measured by the
Preclinical Pharmacology Core at UT Southwestern Medical School. All animal work
was approved and conducted under the oversight of the UT Southwestern Institutional
Animal Care and Use Committee, which uses the Guide for the Care and Use of
Laboratory Animals when establishing animal research standards. Mice were main-
tained at 20.5–22.2 °C, at 48–52% humidity, with light/dark alternating every 12 h. 21
6-week-old female CD-1 (Charles River) mice were dosed intraperitoneally (IP) with
10mg/kg azoffluxin. Azoffluxin was formulated at 1mg/mL in 25% PEG-400 (Sigma);
10% DMSO; 0.1% Tween-80 (Sigma), and 65% ddH2O. At the indicated times post
dose (n= 3 per time point), mice were bled via a submandibular site and whole blood
was collected in lavender top K2EDTA tubes. Plasma was processed from whole blood
by centrifugation at 9600×g for 10min. In total, 50 µL plasma was either used straight
or was diluted in commercial K2EDTA CD-1 plasma (BioIVT) and mixed with 100 µL
of methanol containing 0.15% formic acid, 3mM Ammonium Acetate, and 37.5 ng/
mL N-benzylbenzamide internal standard. The mixture was vortexed, incubated for
10min at room temperature, and then centrifuged at 16,100 g for 5min. Supernatant
was collected and recentrifuged. The final supernatant was analyzed by LC-MS/MS.
Analytical standards and quality control samples were prepared in a similar fashion by
spiking commercial K2EDTA CD-1 mouse plasma with known quantities of azof-
fluxin. Chromatography conditions were as follows: an Agilent (Santa Clara) C18
XDB, 5 µm packing, 50 × 4.6mm size column was used for reverse phase chromato-
graphy. Buffer A consisted of dH2O+ 2mM NH4 acetate and 0.1% formic acid and
Buffer B consisted of methanol+ 2mM NH4 acetate and 0.1% formic acid. Gradient
conditions utilized were: 0.01–0.5min 3% B, 0.5–1.5min gradient to 100% B,1.5–2.5
min 100% B, 2.5–2.6min gradient to 3% B, 2.6–3.6min 3% B. A 619.9 to 286.1
transition was used to quantitate azoffluxin while the 619.9 to 384.2 transition was
used as the qualifier ion pair. N-benzylbenzamide (212.1 to 91.1 transition) was used
as an internal standard. Data were analyzed using Analyst software (AB Sciex.; version
1.7.1) A value 3x above the signal obtained in the blank plasma was designated as the
limit of detection (LOD). The limit of quantitation (LOQ) was defined as the lowest
concentration on the standard curve at which back calculation yielded a concentration
within 20% of the theoretical value and above the LOD signal. The LOQ for azoffluxin
was 0.1 ng/ml. Pharmacokinetic properties were evaluated using the noncompart-
mental analysis tool in WinNonlin (Certara, Corp.; Phoenix WinNonlin version 8.1).
Sparse sampling was used for data analysis. Terminal half-life was calculated as the ln
(2)/λz where λz is a first order rate constant associated with the terminal (log-linear)
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portion of the curve. It is estimated by linear regression of time vs. log concentration
by the software for three or more of the final nonzero data points. Tmax (time to
maximal drug concentration) and Cmax (maximal drug concentration) were deter-
mined by visual inspection. Area under the concentration time curve (AUClast) from
time 0 to the last observed concentration was determined by linear trapezoidal ana-
lysis. Apparent Volume of Distribution (Vz_F) is based on the terminal phase and is
calculated as Dose/λz*AUCinf_obs while Apparent Clearance (CL_F) is calculated as
Dose/AUCinf_obs. Calculation of Absolute Vz and CL requires knowledge of IP
bioavailability (F) which is calculated as AUCIP/AUCiv X Doseiv/DoseIP but was not
determined here because an iv PK was not performed. Mean residence time (MRTlast)
is the average time a molecule of drug spends in the system before before the last
measurable concentration and is calculated by dividing the area under the curve
formed by time and the product of concentration and time (AUMC) divided by
the AUC.
The in vivo tolerability of azoffluxin was determined in outbred ICR (CD-1)
mice (Envigo). Animal toxicity studies were approved by the Institutional
Animal Care and Use Committee of The Lundquist Institute for Biomedical
Innovation at Harbor-UCLA Medical Center (#31413), according to the NIH
guidelines for animal housing and care. Mice were maintained at 20.5–22.2 °C,
at 30–70% humidity, with light/dark alternating every 12 h. Mice weighing ~ 25
g were rendered neutropenic by administration of two doses of
cyclophosphamide (200 mg/kg; Sandoz) given IP and cortisone acetate (250 mg/
kg; Sigma-Aldrich) given subcutaneously on day −2 and +3, relative to
treatment. To prevent bacterial infection, mice received antibacterial
prophylaxis consisting of 50 μg/mL enrofloxacin (Bayer) in the drinking water
starting the same day of immunosuppression. Mice were treated with 10 mg/kg
of azoffluxin formulated as described above twice daily for 4 days or left
untreated (n= 5). Mice were monitored twice daily for signs of distress such as
hunching, ruffled fur, weight loss, difficulty moving, or reduced drinking or
eating to prevent and minimize unnecessary pain for 21 days.
The antifungal activity of azoffluxin was assessed using a well-characterized
model49. All animal procedures were approved by the Institutional Animal Care and
Use Committee at the University of Wisconsin and William S Middleton VA
according to guidelines of the Animal Welfare Act (#DA0081), The Institute of
Laboratory Animal Resources Guide for the Care and Use of Laboratory Animals, and
Public Health Service Policy. Mice were maintained at 22.2 °C, at 45% humidity, with
light/dark alternating every 12 h. Specific-pathogen-free, six-week-old female
ICR (CD-1) mice weighing 23 to 27 g were used (Envigo). Mice were rendered
neutropenic by cyclophosphamide (Mead Johnson Pharmaceuticals) subcutaneous
injection 4 days (150mg/kg) and 1 day (100mg/kg) before infection and 2 days after
infection (100mg/kg). C. auris isolate B11801was subcultured on SDA 24 h prior to
infection. The inoculum was prepared by placing three to five colonies into 5mL of
sterile pyrogen-free 0.9% saline that had been warmed to 35 °C. The final inoculum
was adjusted to a 0.6 transmittance at 530 nm. Final inoculum was determined to be
5.97 ± 0.03 log10 CFU/mL. Disseminated infection was achieved by injection of 0.1mL
of inoculum via the lateral tail vein 2 h prior to the start of drug therapy. Mice were
treated with either saline as a control, fluconazole 32mg/kg administered
subcutaneously every 12 h, azoffluxin 10mg/kg administered IP every 6 h, or
fluconazole 32mg/kg administered subcutaneously every 12 h and azoffluxin 10mg/kg
administered IP every 6 h. Animals were monitored every 6 h for signs of distress.
Mice displaying hunching, ruffled fur, difficulty moving, or reduced drinking or eating
were immediately euthanized. Mice were treated for 96 h, then sacrificed by CO2
asphyxiation. After sacrifice, the kidneys of each mouse were removed and placed in
sterile 0.9% saline at 4 °C. Kidney homogenates were prepared and serially diluted 1:10.
Aliquots were plated on SDA for viable fungal colony counts after incubation for 24 h
at 35 °C. The lower limit of detection was 100 CFU/mL. Results were expressed as the
mean number of CFU per kidney for three mice. Controls were sampled at the start
and end of the 96-hour treatment period. These experiments were performed in two
replicates.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Flow cytometry data collected for this study and its analysis is included as Supplementary
Data 1. Additional data that supports the findings of this study are available from the
corresponding author upon reasonable request. Source data are provided with this paper.
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